As H5N1 spreads in cows, experts warn against drinking raw milk

RobertF.Bukaty/APScientistswhoknowaboutthetypesofpathogens—E.coliandSalmonellaamongthem— thatcanbetr PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen




knowledge

author：Wikipedia    Page View：25554
Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT
The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico. 

advertisement

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank
Next article： Walensky prepares to leave CDC — and Congress — behind